Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @biosimilars101
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @biosimilars101
-
New review: the nocebo effect may contribute to treatment failures when patients are switched from an originator
#biologic to a#biosimilar. Better patient education is among the authors' recommendationshttps://www.centerforbiosimilars.com/news/nocebo-effect-may-have-role-in-some-treatment-failures-adverse-events-in-nonmedical-switching- …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
biosimilars101 proslijedio/la je Tweet
Chronic diseases such as Rheumatoid Arthritis (RA) represent a lifelong burden on patients and their caregivers.
#Biosimilar adoption has the potential to broaden access to high-quality medicines for patients living with#RA.pic.twitter.com/G0AAjT0D1KHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dr. Sarah Yim, Director of the Office of
@US_FDA's OTBB, hopes to see comparable robustness of the U.S.#biosimilars market to the European market in 10 yearshttps://pink.pharmaintelligence.informa.com/PS141542/US-FDAs-Yim-Hopes-To-See-EuropeanLike-Robustness-For-US-Biosimilars-Market-In-10-Years …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
biosimilars101 proslijedio/la je Tweet
"Congress can — and should — do more to create a policy environment that is ripe for biosimilar adoption," says
@RepPaulTonko (D-NY) on the House floor on December 12. Watch for more: https://www.c-span.org/video/?c4838382/user-clip-tonko-biosimilars …#biosimilars#UShealthpic.twitter.com/Vglyd0MWgV
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#Biosimilar education among physicians remains important, but the education of nurses should not be overlooked as a result, explains@lisaksheldon of@OncologyNursinghttps://www.biosimilardevelopment.com/doc/the-nurse-s-perspective-on-biosimilars-in-oncology-care-0001 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
President and CEO of
@AccessibleMeds,@chesterdavisjr, says a combination of perception, fearmongering, and lobbying initiatives has kept#biosimilars market penetration low compared to Europehttps://pharmaboardroom.com/interviews/chip-davis-president-ceo-association-for-accessible-medicines-aam-usa/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Report by
@JYazdanyMD: "[#Biosimilars'] sales in Europe continue to rapidly expand and robust cost savings have materialized." via@BioPharmaReporthttps://www.biopharma-reporter.com/Article/2020/01/17/Mixed-views-on-US-biosimilar-market-in-2020 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Where
#biosimilars are the correct treatment option, providers' failure to prescribe them is a failure to address "financial toxicity," says@OubreKathy in@EBOncologyhttps://www.ajmc.com/journals/evidence-based-oncology/2019/december-2019/empower-physicians-to-fight-financial-toxicity-with-biosimilars …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
biosimilars101 proslijedio/la je Tweet
We applaud the
@US_FDA's draft guidance on interchangeable insulin. Greater competition from biosimilar insulins offers the promise of significant savings and increased access for diabetes patients. Read full comments: https://biosimilarscouncil.org/news/fdas-draft-guidance-on-interchangeable-insulin/ …#insulin#biosimilarspic.twitter.com/ZGn1dbpVh8
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Biosimilars present a "great opportunity" in community oncology," says Tesh Khulla, Senior VP and Advisor at
@flatironhealthhttps://www.centerforbiosimilars.com/interviews/tesh-khullar-biosimilars-in-community-oncology …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
“There’s a lot of promise in the market going forward. We feel like the FDA is putting a good blueprint together, there seems to be legislation, and there are things that are very promising that will increase competition in the
#biosimilars market.”https://www.fiercepharma.com/pharma/education-and-strategy-are-key-to-nurturing-biosimilars-for-success …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
biosimilars101 proslijedio/la je Tweet
#ICYMI:@OubreKathy, COO of Pontchartrain Cancer Center: "The availability of#biosimilars introduces competition based on price, offering a lower-cost alternative in the short term and helping to restrict—or even reverse—longer-term price growth."https://bit.ly/2s8JZjnHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Kashyap Patel, MD says that
#biosimilars’ safety and efficacy have already been established--what is needed is intensive education in the U.S.https://www.fiercepharma.com/pharma/education-and-strategy-are-key-to-nurturing-biosimilars-for-success …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
biosimilars101 proslijedio/la je Tweet
#Biosimilars bring better access and better health outcomes. A strong evidence base is the foundation of physician and patient confidence.pic.twitter.com/iQLLJNGF9X
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
"In order for patients to have access to more affordable
#generics and#biosimilars, patent reform must be a priority in any policy aiming to prevent the prescription drug pricing crisis from getting any worse." Via@rollcallhttps://www.rollcall.com/news/opinion/drug-prices-big-pharma-patent-reform-bipartisan …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The soaring costs of drugs in the U.S. is largely a result of spending on specialty biologic agents. While many analysts including
@USCBO predict#biosimilars would curb spending, barriers remain says@JYazdanyMD in an editorial. Via@medpagetodayhttps://www.medpagetoday.com/rheumatology/generalrheumatology/84391 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Kashyap Patel, MD says his "biggest request" to
#biosimilar manufacturers is that they use all possible avenues to raise awareness of the medicines among providershttps://www.fiercepharma.com/pharma/education-and-strategy-are-key-to-nurturing-biosimilars-for-success …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
biosimilars101 proslijedio/la je Tweet
FDA-approved trastuzumab
#biosimilars are expected to decrease the financial toxicity of#breastcancer treatment#bcsmhttp://ow.ly/QlNY50y1lUwHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#DYK: Some patients forego filling critically needed prescriptions, bypass diagnostic tests, and fail to make appointments with their providers due to the high cost of cancer care?https://ascopubs.org/doi/10.1200/JOP.18.00120 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The FDA-approval of
#biosimilars to treat breast cancer is expected to decrease the financial burden of treating the diseasehttps://www.onclive.com/web-exclusives/experts-highlight-benefits-and-challenges-with-biosimilars-in-breast-cancer …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.